At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 156 enrolled
Drug / intervention
Flortaucipir F18 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
In Brief
A Phase 3 clinical trial evaluating Flortaucipir F18 and PET Scan for Alzheimer's Disease. Completed, enrolled 156 participants across 31 sites in 2 countries.
Detailed Summary
This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesAustralia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartSep 2015
Primary CompletionJun 2018
Study CompletionJul 2018
TodayJul 2026
First PostedAug 5, 2015
Enrollment StartSep 1, 2015
Primary CompletionJun 13, 2018
Study CompletionJul 15, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.9 years ago
Interventions
Flortaucipir F18drug
370 megabecquerel (MBq) IV single-dose
PET Scanprocedure
positron emission tomography (PET) scan